Literature DB >> 1706955

Growth factor requirements of childhood acute T-lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro.

R O'Connor1, A Cesano, B Lange, J Finan, P C Nowell, S C Clark, S C Raimondi, G Rovera, D Santoli.   

Abstract

Cells from 10 cases of childhood acute T-lymphoblastic leukemia (T-ALL) were cultured in the presence of recombinant human interleukins (rhIL) or colony-stimulating factors (CSF) to analyze their growth factor requirements and differentiative potential. Although cells from most leukemic samples displayed a short-term proliferative response to several hematopoietic growth factors, only the ones featuring chromosomal translocations could be established as permanent cell lines. Two cell lines could be initiated only in the presence of IL-3 (TALL-103 and TALL-106), one in granulocyte-macrophage CSF (GM-CSF) (TALL-101), and one in IL-2 (TALL-104); only one cell line (TALL-105) was originated in the absence of growth factors. The TALL-101 and TALL-103 cell lines, derived from very immature T-ALL cases, underwent growth factor-dependent phenotypic conversion (lymphoid to myeloid). However, the T-cell receptor rearrangement and karyotype of the original leukemic clones were retained. In contrast, the TALL-104, -105, and -106 cell lines which originated from more mature T-ALL cases, maintained a T-lymphoblastic phenotype regardless of the growth factors in which they were expanded. These data demonstrate in vitro the aggressive nature of T-ALL cases bearing chromosomal abnormalities, and indicate that the lineage commitment of the malignant clone depends on its stage of maturation in T-cell ontogeny.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706955

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Effect of the disintegrin eristostatin on melanoma-natural killer cell interactions.

Authors:  Stefan Hailey; Elizabeth Adams; Ryan Penn; Alice Wong; Mary Ann McLane
Journal:  Toxicon       Date:  2012-11-09       Impact factor: 3.033

2.  Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.

Authors:  A Cesano; S Visonneau; L Cioé; S C Clark; G Rovera; D Santoli
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

3.  Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.

Authors:  German G Gomez; Susana B Read; Lazaro E Gerschenson; Daniela Santoli; Adam Zweifach; Carol A Kruse
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

4.  Inducible expression of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and interferon-gamma in two human cytotoxic leukemic T-cell lines.

Authors:  A Cesano; D Santoli
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

5.  Two unique human leukemic T-cell lines endowed with a stable cytotoxic function and a different spectrum of target reactivity analysis and modulation of their lytic mechanisms.

Authors:  A Cesano; D Santoli
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

6.  Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.

Authors:  A Cesano; S Visonneau; L Cioé; S C Clark; D Santoli
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

7.  Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.

Authors:  German G Gomez; Carol A Kruse
Journal:  J Immunother       Date:  2007-04       Impact factor: 4.456

8.  Increased cystatin F levels correlate with decreased cytotoxicity of cytotoxic T cells.

Authors:  Mateja Prunk; Milica Perisic Nanut; Jerica Sabotic; Urban Svajger; Janko Kos
Journal:  Radiol Oncol       Date:  2019-03-03       Impact factor: 2.991

9.  Antileukemic activity of sulforaphane in primary blasts from patients affected by myelo- and lympho-proliferative disorders and in hypoxic conditions.

Authors:  Carmela Fimognari; Eleonora Turrini; Piero Sestili; Cinzia Calcabrini; Giovanni Carulli; Giulia Fontanelli; Martina Rousseau; Giorgio Cantelli-Forti; Patrizia Hrelia
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.